References
- Caers J, Vandebroek I, de Raeve H et al. Multiple myeloma. An update on diagnosis and treatment. Eur J Haematol 2008; 81: 329–343.
- Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients withnewly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.
- Ruiz-Delgado GJ, Ruiz-Arguelles GJ. Genetic predisposition for monoclonal gammopathy of undetermined significance. Mayo Clin Proc 2008; 83: 601–603.
- Ruiz-Arguelles GJ, Gomez-Rangel D, Ruiz-Delgado GJ, Aguilar-Romero L. Multiple myeloma in Mexico: a single institution, twenty-year experience. Arch Med Res 2004; 35: 163–167.
- Dune BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854.
- Greipp PR, San Miguel JF, Dune BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.
- Greipp PR, Trendle MC, Leong T et al. Is flow cytometric DNAcontent hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma 1999: 35: 83–89.
- Hata H, Matsuzaki H, Yoshida M et al. Hyperdiploid myeloma cell as an indicator of poor prognosis and drug refractoriness. Int .1 Hematol 1997; 66: 219–226.
- Vindelov LL, Christensen U., Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1985; 6: 348–365
- Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3–9.
- San Miguel JF, Garcia-Sanz R, Gonzalez M, °rida A. DNA cell content studies in multiple myeloma. Leuk Lymphoma 1996; 23: 33–41.
- Avet-Loiseau H, Attal M. Moreau P et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489–3495.